---
title: CDMO Daily News — October 3, 2026
slug: daily-news-2026-10-03-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: October 3 CDMO daily: Biomay and Synthego Partner on Integrated cGMP CRISPR Manufacturing; Lonza and Asimov Partner on Scalable Lentiviral Vector…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-10-03-cdmo
published_at: 2026-10-03T00:02:12.306Z
last_updated: 2026-10-03T00:04:36.412Z
---

### [Biomay](/companies/biomay) and [Synthego](/companies/synthego) Partner on Integrated cGMP CRISPR Manufacturing
- [Biomay](/companies/biomay) will resell its mRNA, LNP formulation, aseptic fill-finish, plasmid DNA, recombinant proteins, and Cas9 production services to [Synthego](/companies/synthego) customers under a non-exclusive collaboration.
- Synthego customers gain access to Biomay's off-the-shelf and cGMP Cas9 products, plus integrated cGMP solutions combining mRNA manufacturing, LNP formulation, fill-finish, and Cas9 production with Synthego's sgRNA expertise.
- The partnership streamlines end-to-end manufacturing pathways for CRISPR-based therapies across North America, including custom cGMP mRNA and LNP formulation services for gene-editing programs.

**Operational Impact**

CDMO directors evaluating CRISPR manufacturing capacity should note that [Biomay](/companies/biomay)'s existing cGMP mRNA, LNP, fill-finish, and Cas9 production capabilities are now marketed directly to [Synthego](/companies/synthego)'s customer base, potentially reducing standalone vendor selection complexity for integrated gene-editing programs.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/biomay-synthego-partner-to-streamline-cgmp-crispr-manufacturing-services)*

---

### [Lonza](/companies/lonza) and [Asimov](/companies/asimov) Partner on Scalable Lentiviral Vector Manufacturing for Gene Therapy
- [Lonza](/companies/lonza) and [Asimov](/companies/asimov) are collaborating to advance lentiviral vector manufacturing using Asimov's LV Edge stable producer cell lines combined with Lonza's process development, scale-up, and GMP capabilities.
- The partnership addresses manufacturability challenges in current multi-plasmid transient transfection methods by developing stable, program-specific production strategies to improve scalability and batch-to-batch consistency.
- The companies will establish a feasibility-first framework spanning transgene optimization, cell line development, process development, analytics, scale-up, GMP production, and CMC readiness for in vivo and ex vivo lentiviral programs.

**Operational Impact**

[Lonza](/companies/lonza)'s integration of [Asimov](/companies/asimov)'s LV Edge stable producer cell lines into its GMP manufacturing platform expands the CDMO's specialized modalities portfolio and positions it as a preferred partner for developers seeking earlier manufacturability input and faster paths to clinical and commercial lentiviral vector production.

*Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/lonza-asimov-partner-to-advance-scalable-lentiviral-vector-manufacturing)*

## References

1. [Contract Pharma Breaking News RSS — Biomay and Synthego Partner on Integrated cGMP CRISPR Manufacturing](https://www.contractpharma.com/breaking-news/biomay-synthego-partner-to-streamline-cgmp-crispr-manufacturing-services)
2. [Contract Pharma Breaking News RSS — Lonza and Asimov Partner on Scalable Lentiviral Vector Manufacturing for Gene Therap](https://www.contractpharma.com/breaking-news/lonza-asimov-partner-to-advance-scalable-lentiviral-vector-manufacturing)

Source: https://www.cdmo.directory/posts/daily-news-2026-10-03-cdmo